CAPR vs. GLSI, MCRB, SCPH, GOSS, IVA, PRQR, TELO, OGI, SKYE, and ALIM
Should you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include Greenwich LifeSciences (GLSI), Seres Therapeutics (MCRB), scPharmaceuticals (SCPH), Gossamer Bio (GOSS), Inventiva (IVA), ProQR Therapeutics (PRQR), Telomir Pharmaceuticals (TELO), Organigram (OGI), Skye Bioscience (SKYE), and Alimera Sciences (ALIM). These companies are all part of the "pharmaceutical preparations" industry.
Capricor Therapeutics (NASDAQ:CAPR) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, community ranking, valuation, analyst recommendations and dividends.
Capricor Therapeutics received 340 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 62.73% of users gave Capricor Therapeutics an outperform vote while only 33.33% of users gave Greenwich LifeSciences an outperform vote.
21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 12.0% of Capricor Therapeutics shares are owned by insiders. Comparatively, 52.9% of Greenwich LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Capricor Therapeutics presently has a consensus target price of $21.75, suggesting a potential upside of 250.81%. Greenwich LifeSciences has a consensus target price of $36.00, suggesting a potential upside of 157.51%. Given Capricor Therapeutics' higher possible upside, analysts plainly believe Capricor Therapeutics is more favorable than Greenwich LifeSciences.
Greenwich LifeSciences has a net margin of 0.00% compared to Capricor Therapeutics' net margin of -89.72%. Greenwich LifeSciences' return on equity of -93.88% beat Capricor Therapeutics' return on equity.
Greenwich LifeSciences has lower revenue, but higher earnings than Capricor Therapeutics. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Capricor Therapeutics had 32 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 33 mentions for Capricor Therapeutics and 1 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 0.59 beat Capricor Therapeutics' score of -0.16 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.
Capricor Therapeutics has a beta of 4.06, indicating that its share price is 306% more volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.
Summary
Capricor Therapeutics beats Greenwich LifeSciences on 10 of the 16 factors compared between the two stocks.
Get Capricor Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Capricor Therapeutics Competitors List
Related Companies and Tools
